What Kano Therapeutics does

Kano Therapeutics is an MIT spinout founded in 2021 that develops circular single-stranded DNA (cssDNA) templates, marketed as KanoDNA, for use as genetic payloads in cell and gene therapy applications. The company's core technology addresses what it characterizes as a fundamental industry bottleneck: the lack of high-quality, scalable DNA donor templates for precise gene editing. KanoDNA is engineered at the topology and 3D-feature level to influence stability, intracellular behavior, and downstream performance, with the company reporting 3-5X more edited cells compared to alternative DNA templates in homology-directed repair workflows using CRISPR nucleases. The platform is indication-, disease-, and technology-agnostic and is positioned for use in CAR-T and gene correction therapies, targeted insertion with recombinase or transposon systems, and non-integrating episomal expression of programmable genetic constructs. Manufacturing uses industrial fermentation analogous to biologics and plasmid DNA production rather than traditional chemical or enzymatic methods, which the company argues resolves the economic scalability barrier of conventional ssDNA production.

The company's go-to-market is enterprise B2B, licensing DNA products and supplying them through integrated partnerships with biotechnology and pharmaceutical companies. Kano's commercial motion starts with low-friction evaluation agreements that let partners generate data in their own systems, then progresses to full partnerships with integrated DNA supply spanning discovery through GMP. The integrated platform combines three core functional units: design, manufacturing, and screening, marketed as a one-stop solution. Kano serves two primary customer segments: cell and gene therapy developers and gene editing technology companies. Pricing is not publicly disclosed; the model aligns with licensing/royalty and supply agreements typical of platform reagent and CDMO-style biotechs. No customer logos or revenue figures are disclosed, and the company is pre-commercial at the seed stage.

Kano was co-founded by Dr. Floris Engelhardt (CEO/CSO), a physicist with a PhD from the Technical University of Munich who completed her postdoctoral work in Mark Bathe's BatheBioNano lab at MIT, and John Vroom (CBO), an MIT Sloan MBA with prior life sciences consulting experience across 50+ engagements. The company is headquartered at 238 Main Street, Cambridge, MA 02142, and operates with a team of approximately 10-15 including founders, Director CMC, Lead Platform Engineering, Lead Preclinical Biology, a Senior Research Associate, and an undergraduate co-op. Disclosed total funding is $7.1 million, anchored by an oversubscribed $5 million seed round in August 2024 co-led by The Engine Ventures and VSquared Ventures with Taihill Venture and Metaplanet participating, plus a $2.1M round in 2022. 2025 strategic actions include a collaboration with Merck KGaA announced September 4, acceptance into the NVIDIA Inception program on September 3, and receipt of a Massachusetts Manufacturing Innovation Initiative (M2I2) grant on October 29. Seth Ettenberg was appointed as an independent board director with BlueRock Therapeutics lineage.

Name

Kano Therapeutics

Legal name

Kano Therapeutics

Website

https://kanotherapeutics.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

11–50 employees

Short description

Kano Therapeutics is an MIT spinout that develops circular single-stranded DNA templates branded as KanoDNA, licensing them as scalable genetic payloads for cell and gene therapy developers and gene editing companies via integrated partnerships from discovery through GMP.

Ownership category

akta.pro rank

Product category

Cell and Gene Therapy DNA Templates

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream) (HLAAACAN)

akta.pro secondary industries

mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA) (HLAGAGAC), Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development) (HLAAAIAD)

Keywords

• Circular single-stranded DNA
• Gene editing templates
• Cell and gene therapy
• DNA payload manufacturing
• Non-viral gene insertion

Headquarters

HQ city

Cambridge

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales

Revenue model

1. DNA Product Licensing and Supply: License DNA products and supply them through integrated partnerships. Partners access evaluation agreements, then full partnerships with integrated DNA supply from discovery through GMP.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Kano Therapeutics develops and manufactures KanoDNA, a circular single-stranded DNA (cssDNA) template used as a gene-editing payload for cell and gene therapy developers. The company licenses its cssDNA products and supplies them through integrated partnerships spanning discovery, process development, and GMP manufacturing. Production relies on a proprietary fermentation-based process rather than traditional chemical or enzymatic synthesis, enabling scalable, GMP-ready supply of high-fidelity, immune-quiet DNA templates for applications such as HDR with CRISPR, recombinase/transposon insertion, and episomal expression.

Product overview

Kano Therapeutics operates as a single unified platform built around its KanoDNA circular single-stranded DNA (cssDNA) product, which connects three core functional units: design, manufacturing, and screening. The platform offers DNA products and integrated partnership services, enabling partners to license DNA products and access full support from discovery through GMP supply. KanoDNA functions as the missing payload layer in cell and gene therapy, supporting applications including HDR with CRISPR nucleases for CAR-T and gene correction therapies, targeted insertion with next-generation editing tools, and non-integrating DNA templates for episomal expression. The platform is indication-, disease-, and technology-agnostic, designed to enable the broadest therapeutic impact across genetic medicine.

Differentiator

Problem solved

Functional benefit

Products and services

• KanoDNA (circular single-stranded DNA / cssDNA) Circular single-stranded DNA templates designed for high-fidelity gene editing, immune-quiet delivery, and scalable manufacturing via fermentation-based production. Used by cell and gene therapy developers for HDR with CRISPR nucleases, targeted insertion with recombinase or transposon systems, and non-integrating episomal expression of programmable genetic constructs. Offered through integrated licensing and supply partnerships from discovery through GMP.

Quantifiable outcome

• 3-5X more edited cells than other DNA templates in HDR with CRISPR nucleases

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• Merck KGaA, Darmstadt, GermanycoreStrategic or Co-development Partner · 4 September 2025Collaboration announced in September 2025. Nature of collaboration focused on DNA templates and genetic medicine development.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Integrated DNA Technologies (IDT): IDT is a leading global supplier of custom oligonucleotides and nucleic acid reagents, including ssDNA and dsDNA donors used in gene editing. It is the closest incumbent comparable in supplying research-through-GMP DNA for cell and gene therapy developers, though it does not specialize in circular ssDNA.
• GenScript: GenScript offers gene synthesis, plasmid manufacturing, and cell therapy services including DNA and protein reagents for gene editing. It is a comparable incumbent supplying DNA templates and related services to the cell and gene therapy ecosystem.
• Eurofins Genomics: Eurofins Genomics offers DNA synthesis, gene synthesis, and oligonucleotide manufacturing services globally. It is a broader incumbent supplying custom DNA to research and therapeutic customers, with overlap in the gene therapy DNA template market.

Direct peers

• Twist Bioscience: Twist provides synthetic DNA and gene fragments at scale using a silicon-based DNA writing platform, serving antibody discovery, synthetic biology, and gene therapy applications. It competes directly with Kano in providing engineered DNA payloads for next-generation therapeutics.
• Aldevron: Aldevron (now part of Danaher) manufactures plasmid DNA, mRNA, and proteins used in gene and cell therapies, including as donor templates. It is a direct comparable in GMP-grade nucleic acid manufacturing for cell and gene therapy developers.
• Synthego: Synthego supplies synthetic guide RNAs and gene editing tools, including engineered DNA/RNA reagents for cell and gene therapy developers. It is directly comparable as a developer of nucleic acid payloads serving the same gene editing customer base.
• TriLink BioTechnologies: TriLink (part of Maravai LifeSciences) manufactures mRNA, plasmid DNA, and nucleic acid reagents for therapeutic and vaccine applications. It is a direct peer as a GMP-grade nucleic acid supplier to cell and gene therapy developers.

Emerging players

• Codex DNA: Codex DNA (formerly Synthetic Genomics) develops automated DNA synthesis and assembly platforms for synthetic biology and therapeutic applications. It overlaps with Kano in providing synthetic DNA building blocks for advanced therapeutics.
• Ansa Biotechnologies: Ansa is developing enzymatic DNA synthesis technology to produce long, high-fidelity oligonucleotides and gene fragments. It is an emerging competitor targeting the same DNA payload / template need for gene therapy and synthetic biology.
• DNA Script: DNA Script builds enzymatic DNA synthesis platforms (Syntax platform) for producing oligonucleotides on demand. It is comparable to Kano as an alternative next-generation DNA synthesis approach serving research and therapeutic customers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/kano_tx
• LinkedInlinkedin.com/company/kano-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds3 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Kano Therapeutics